(byoo-ten-a-feen) ,

Lotrimin Ultra

(trade name),


(trade name)


Therapeutic: antifungals
Pregnancy Category: B


Treatment of a variety of cutaneous fungal infections, including tinea pedis (athlete’s foot), tinea cruris (jock itch), tinea corporis (ringworm), and tinea versicolor.


Affects the synthesis of the fungal cell wall.

Therapeutic effects

Decrease in symptoms of fungal infection.


Absorption: Absorption through intact skin is minimal.
Distribution: Distribution after topical administration is primarily local.
Metabolism and Excretion: Hepatic via hydroxylation.
Half-life: 35 hr.

Time/action profile

Topunknownup to 4 wkunknown


Contraindicated in: Hypersensitivity to active ingredients, additives, preservatives, or bases; Some products contain alcohol or bisulfites and should be avoided in patients with known intolerance.
Use Cautiously in: Nail and scalp infections (may require additional systemic therapy); Obstetric / Lactation: Safety not established.

Adverse Reactions/Side Effects


  • burning
  • itching
  • local hypersensitivity reactions
  • redness
  • stinging


Drug-Drug interaction

None significant.


Topical (Adults and Children > 12 yr) Apply once daily for 2 wk for patients with tinea corporis, tinea cruris, or tinea versicolor. Apply once daily for 4 wk or twice daily for 7 days for patients with tinea pedis.


Cream: 1%Rx, OTC

Nursing implications

Nursing assessment

  • Inspect involved areas of skin and mucous membranes before and frequently during therapy. Increased skin irritation may indicate need to discontinue medication.

Potential Nursing Diagnoses

Risk for impaired skin integrity (Indications)
Risk for infection (Indications)


  • Consult physician or other health care professional for proper cleansing technique before applying medication.
  • Topical: Apply small amount to cover affected area completely. Avoid the use of occlusive wrappings or dressings unless directed by physician or other health care professional.

Patient/Family Teaching

  • Instruct patient to apply medication as directed for full course of therapy, even if feeling better. Emphasize the importance of avoiding the eyes or vaginal area.
  • Caution patient that some products may stain fabric, skin, or hair. Check label information. Fabrics stained from cream can usually be cleaned by handwashing with soap and warm water.
  • Patients with athlete’s foot should be taught to wear well-fitting, ventilated shoes, to wash affected areas thoroughly, and to change shoes and socks at least once a day.
  • Advise patient to report increased skin irritation or lack of response to therapy to health care professional.
  • Early relief of symptoms may be seen in 2–3 days. For tinea cruris, tinea corporis, and tinea versicolor, 2 wk are needed, and for tinea pedis, therapeutic response may take 4 wk. Recurrent fungal infections may be a sign of systemic illness.

Evaluation/Desired Outcomes

  • Decrease in skin irritation and.
  • Resolution of infection.


Butenafine Dermatology An antifungal for tinea corporis, tinea cruris, interdigital tinea pedis, onychomycosis. See Dermatophytosis.
References in periodicals archive ?
Going forward, Mylan plans to focus its antifungal marketing efforts on Mentax, which is already well positioned in the Company's product portfolio.
This press release includes statements that constitute "forward-looking statements," including with regard to the FDA approval of Sertaconazole and the payment to the Company contingent on such approval, and with regard to the Company's branded portfolio including the positioning of Mentax.
Another example of this strategy leased to add their promotion of Mentax to our g used by podiatrists.
The Bertek sales force will add Avita (R) to its current product portfolio which includes Maxzide (R), a once-a-day triamterene hydrochlorothiazide diuretic; Nitrek (R), a nitroglycerin transdermal patch system; Clorpres (R), for hard to treat hypertension; and Mentax (R), a prescription antifungal product co-promoted with Penederm.
Penederm has several other pharmaceutical products for fungal inflammatory conditions, psoriasis, nail fungus and Mentax skin treatment line extensions in human clinical trials.
The first quarter of 1998 reflects product revenues from Avita cream and Mentax and initial product stocking shipments of the Company's recently launched Acticin and Avita gel products.
Product sales increased to $6,341,000 in 1997, compared to $2,258,000 in 1996, primarily due to the commercial launch of the Company's first two pharmaceutical products, Mentax and Avita.
The increase in product revenues in 1997 reflects the recent launch of Mentax and Avita, which were approved by the U.
We launched MENTAX in the US market early in 1997, along with our co-promotion partner, Schering-Plough Healthcare, Inc.
A substantial portion of first quarter 1997 revenues include initial product stocking shipments of the Company's recently launched Mentax.